CNTX.US Context Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
0.1808 USD
Close of Nov 13, 2026
0.1800 3.62
Market cap
USD 16.6M
P/E
-
P/B
0.59x
ROE
-132.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CNTX.US undervalued?

Graham number

The Graham number of Context Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Context Therapeutics Inc fundamental analysis

No fundamental analysis for Context Therapeutics Inc yet.

Context Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Context Therapeutics Inc

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The comp…

Full company profile